Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609).
Adams S, Othus M, Patel SP, Miller KD, Chugh R, Schuetze SM, Chamberlin MD, Haley BJ, Storniolo AMV, Reddy MP, Anderson SA, Zimmerman CT, O'Dea AP, Mirshahidi HR, Ahnert JR, Brescia FJ, Hahn O, Raymond JM, Biggs DD, Connolly RM, Sharon E, Korde LA, Gray RJ, Mayerson E, Plets M, Blanke CD, Chae YK, Kurzrock R. Adams S, et al. Among authors: chamberlin md. Clin Cancer Res. 2022 Jan 15;28(2):271-278. doi: 10.1158/1078-0432.CCR-21-2182. Epub 2021 Oct 29. Clin Cancer Res. 2022. PMID: 34716198 Free PMC article. Clinical Trial.
Preventing metastatic recurrence in low-risk ER/PR + breast cancer patients-a retrospective clinical study exploring the evolving challenge of persistence with adjuvant endocrine therapy.
Kuhn EP, Pirruccello J, Boothe JT, Li Z, Tosteson TD, Stahl JE, Schwartz GN, Chamberlin MD. Kuhn EP, et al. Among authors: chamberlin md. Breast Cancer Res Treat. 2023 Feb;198(1):31-41. doi: 10.1007/s10549-022-06849-0. Epub 2023 Jan 2. Breast Cancer Res Treat. 2023. PMID: 36592233 Free PMC article.
Alternating 17β-Estradiol and Aromatase Inhibitor Therapies Is Efficacious in Postmenopausal Women with Advanced Endocrine-Resistant ER+ Breast Cancer.
Schwartz GN, Kaufman PA, Giridhar KV, Marotti JD, Chamberlin MD, Arrick BA, Makari-Judson G, Goetz MP, Soucy SM, Kolling F, Demidenko E, Miller TW. Schwartz GN, et al. Among authors: chamberlin md. Clin Cancer Res. 2023 Aug 1;29(15):2767-2773. doi: 10.1158/1078-0432.CCR-23-0112. Clin Cancer Res. 2023. PMID: 37260292 Free PMC article.
Plasma DNA as a "liquid biopsy" incompletely complements tumor biopsy for identification of mutations in a case series of four patients with oligometastatic breast cancer.
Chamberlin MD, Wells JD, Shee K, Bean JR, Marotti JD, Wells WA, Trask HW, Kolling FW, Bhatt A, Kaufman PA, Schwartz GN, Gemery JM, McNulty NJ, Tsapakos MJ, Barth RJ, Arrick BA, Gui J, Miller TW. Chamberlin MD, et al. Breast Cancer Res Treat. 2020 Aug;182(3):665-677. doi: 10.1007/s10549-020-05714-2. Epub 2020 Jun 19. Breast Cancer Res Treat. 2020. PMID: 32562118 Free PMC article.
Differential effects of CD20+ B cells and PD-L1+ immune cells on pathologic complete response and outcome: comparison between inflammatory breast cancer and locally advanced breast cancer patients.
Arias-Pulido H, Cimino-Mathews AM, Chaher N, Qualls CR, Joste N, Colpaert C, Marotti JD, Chamberlin MD, Foisey MG, Prossnitz ER, Emens LA, Fiering S. Arias-Pulido H, et al. Among authors: chamberlin md. Breast Cancer Res Treat. 2021 Dec;190(3):477-489. doi: 10.1007/s10549-021-06391-5. Epub 2021 Sep 20. Breast Cancer Res Treat. 2021. PMID: 34542773 Free PMC article.
Cutaneous breast cancer of unknown primary.
Salem I, Bennett R, Hodson EL, Duprat GE, Doughty H, Georgantzoglou N, Linos K, Chamberlin MD, Chapman MS. Salem I, et al. Among authors: chamberlin md. JAAD Case Rep. 2023 Apr 6;37:45-48. doi: 10.1016/j.jdcr.2023.03.013. eCollection 2023 Jul. JAAD Case Rep. 2023. PMID: 37324179 Free PMC article. No abstract available.
34 results